Hazlett, Burt & Watson, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Hazlett, Burt & Watson, Inc.
- $222 Million
- Q1 2025
A detailed history of Hazlett, Burt & Watson, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Hazlett, Burt & Watson, Inc. holds 150 shares of RXRX stock, worth $685. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150Holding current value
$685% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding RXRX
# of Institutions
365Shares Held
286MCall Options Held
3.28MPut Options Held
3.16M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl34.8MShares$159 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.3MShares$148 Million0.0% of portfolio
-
Baillie Gifford & CO24.4MShares$111 Million0.12% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$79.1 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$67 Million0.27% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $825M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...